Sana Biotechnology, Inc. (SANA) Stock
6 of the hedge funds AlphaScala tracks reported SANA in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Marshall Wace's at $10.23M.
Which hedge funds own SANA?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Marshall Wace | 2.93M | $10.23M | +341% |
| Renaissance Technologies Jim Simons (founder) | 1.23M | $4.30M | -15% |
| Millennium Management Israel Englander | 654K | $2.28M | -59% |
| Point72 Steve Cohen | 595K | $2.08M | NEW |
| Citadel Ken Griffin | 161K | $562.5K | -72% |
| D.E. Shaw David Shaw | 40K | $139.9K | +4% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →SANA price chart
Powered by TradingViewWhat does Sana Biotechnology, Inc. do?
Sana Biotechnology, Inc. is a clinical-stage biotechnology company developing engineered cell therapies to repair and control genes in cells or replace missing or damaged cells, addressing the underlying causes of diseases. The company focuses on two primary platforms: hypoimmune technology, which modifies cells to evade immune rejection for off-the-shelf allogeneic therapies, and in vivo cell engineering using fusogen delivery systems to precisely target and edit genes within patients' bodies. These platforms target oncology with CAR-T programs for B-cell cancers, autoimmune disorders, and type 1 diabetes through beta cell replacement, among other areas. Sana Biotechnology, Inc. emphasizes scalable manufacturing to reduce costs and improve patient access, integrating expertise in stem cell biology, immunology, gene editing, and therapeutics development. Founded in 2018 and headquartered in Seattle, Washington, the company advances a pipeline of innovative candidates designed to transform treatment outcomes in genetic and acquired diseases by overcoming key biological barriers like immune response and delivery challenges.